 | • レポートコード：MRC2211A117 • 出版社/出版日：Transparency Market Research / 2022年8月 • レポート形態：英文、PDF、214ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界の良性前立腺肥大症（BPH）治療市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療別（薬物治療、低侵襲手術、レーザー治療、その他）分析、エンドユーザー別（病院、外来手術センター、専門クリニック、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を掲載しています。なお、当書には、Boston Scientific Corporation、Teleflex Incorporated、Endo International plc、Urologix, LLC、LISA Laser、Olympus Corporationなどの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の良性前立腺肥大症（BPH）治療市場規模：治療別 - 薬物治療の市場規模 - 低侵襲手術の市場規模 - レーザー治療の市場規模 - その他治療の市場規模 ・世界の良性前立腺肥大症（BPH）治療市場規模：エンドユーザー別 - 病院における市場規模 - 外来手術センターにおける市場規模 - 専門クリニックにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の良性前立腺肥大症（BPH）治療市場規模：地域別 - 北米の良性前立腺肥大症（BPH）治療市場規模 - ヨーロッパの良性前立腺肥大症（BPH）治療市場規模 - アジア太平洋の良性前立腺肥大症（BPH）治療市場規模 - 中南米の良性前立腺肥大症（BPH）治療市場規模 - 中東・アフリカの良性前立腺肥大症（BPH）治療市場規模 ・競争状況 |
Benign Prostatic Hyperplasia Treatment Market – Scope of Report
TMR’s report on the global benign prostatic hyperplasia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global benign prostatic hyperplasia treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global benign prostatic hyperplasia treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the benign prostatic hyperplasia treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global benign prostatic hyperplasia treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global benign prostatic hyperplasia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global benign prostatic hyperplasia treatment market.
The report delves into the competitive landscape of the global benign prostatic hyperplasia treatment market. Key players operating in the global benign prostatic hyperplasia treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global benign prostatic hyperplasia treatment market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market benign prostatic hyperplasia treatment.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Benign Prostatic Hyperplasia Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Prevalence of Benign Prostatic Hyperplasia by region/globally
5.3. Re-imbursement Scenario
5.4. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, By Treatment
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Drug Class
6.3.1.1. Alpha-Blockers
6.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
6.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
6.3.1.4. Others
6.3.2. Minimally Invasive Surgeries
6.3.2.1. Transurethral Resection of the Prostate (TURP)
6.3.2.2. Transurethral Incision of the Prostate (TUIP)
6.3.2.3. Robotic Surgeries
6.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
6.3.2.5. Prostatic Urethral Lift
6.3.3. Laser Therapy
6.3.4. Others
6.4. Market Attractiveness Analysis, by Treatment
7. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Hospitals
7.3.2. Ambulatory Surgical Centers
7.3.3. Specialty Clinics
7.3.4. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment, 2017–2031
9.2.1. Drug Class
9.2.1.1. Alpha-Blockers
9.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
9.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
9.2.1.4. Others
9.2.2. Minimally Invasive Surgeries
9.2.2.1. Transurethral Resection of the Prostate (TURP)
9.2.2.2. Transurethral Incision of the Prostate (TUIP)
9.2.2.3. Robotic Surgeries
9.2.2.4. Transurethral Microwave Thermotherapy (TUMT
9.2.2.5. Prostatic Urethral Lift
9.2.3. Laser Therapy
9.2.4. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Specialty Clinics
9.3.4. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment
9.5.2. By End-user
9.5.3. By Country
10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment, 2017–2031
10.2.1. Drug Class
10.2.1.1. Alpha-Blockers
10.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
10.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
10.2.1.4. Others
10.2.2. Minimally Invasive Surgeries
10.2.2.1. Transurethral Resection of the Prostate (TURP)
10.2.2.2. Transurethral Incision of the Prostate (TUIP)
10.2.2.3. Robotic Surgeries
10.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
10.2.2.5. Prostatic Urethral Lift
10.2.3. Laser Therapy
10.2.4. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Hospitals
10.3.2. Ambulatory Surgical Centers
10.3.3. Specialty Clinics
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2031
11.2.1. Drug Class
11.2.1.1. Alpha-Blockers
11.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
11.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
11.2.1.4. Others
11.2.2. Minimally Invasive Surgeries
11.2.2.1. Transurethral Resection of the Prostate (TURP)
11.2.2.2. Transurethral Incision of the Prostate (TUIP)
11.2.2.3. Robotic Surgeries
11.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
11.2.2.5. Prostatic Urethral Lift
11.2.3. Laser Therapy
11.2.4. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.3.3. Specialty Clinics
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2031
12.2.1. Drug Class
12.2.1.1. Alpha-Blockers
12.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
12.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
12.2.1.4. Others
12.2.2. Minimally Invasive Surgeries
12.2.2.1. Transurethral Resection of the Prostate (TURP)
12.2.2.2. Transurethral Incision of the Prostate (TUIP)
12.2.2.3. Robotic Surgeries
12.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
12.2.2.5. Prostatic Urethral Lift
12.2.3. Laser Therapy
12.2.4. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Hospitals
12.3.2. Ambulatory Surgical Centers
12.3.3. Specialty Clinics
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2031
13.2.1. Drug Class
13.2.1.1. Alpha-Blockers
13.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
13.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
13.2.1.4. Others
13.2.2. Minimally Invasive Surgeries
13.2.2.1. Transurethral Resection of the Prostate (TURP)
13.2.2.2. Transurethral Incision of the Prostate (TUIP)
13.2.2.3. Robotic Surgeries
13.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
13.2.2.5. Prostatic Urethral Lift
13.2.3. Laser Therapy
13.2.4. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers
13.3.3. Specialty Clinics
13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Boston Scientific Corporation
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Teleflex Incorporated
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Endo International plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Urologix, LLC
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.5. LISA Laser
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Olympus Corporation
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
Table 01: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031
Table 02: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031
Table 03: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031
Table 04: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 05: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031
Table 08: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031
Table 09: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031
Table 10: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 11: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 12: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 13: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031
Table 14: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031
Table 15: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031
Table 16: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 17: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 18: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 19: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031
Table 20: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031
Table 21: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2031
Table 22: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 23: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 24: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 25: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031
Table 26: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031
Table 27: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031
Table 28: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 29: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 30: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 31: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031
Table 32: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031
Table 33: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031
Table 34: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 35: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031